In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Radiopharmaceutical agents for myocardial perfusion imaging

Nuclear Imaging

In this excellent review Baggish and Boucher (1) review the three currently available radiopharmaceutical agents for myocardial perfusion imaging: Thallium 201, Tetrofosmin and Sestamibi.  They discuss their physical properties, physiological properties, and logistic considerations in clinical practice (including radiation exposure, safety issues, preparation and handling…).  Also cost considerations and clinical performance considerations are explained and discussed.  This excellent review may be of help for all physicians involved in nuclear cardiology.


  1. Baggish A, Boucher C.  Radiopharmaceutical agents for myocardial perfusion imaging.  Circulation 2008;118:1668-1674.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.